News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Onconova Therapeutics Inc. (ONTX) To Present At Rodman & Renshaw 16th Annual Global Investment Conference



9/3/2014 7:43:09 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEWTOWN, Pa., Sept. 3, 2014 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq:ONTX) a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that Ramesh Kumar, Ph.D., President and CEO, will present at the Rodman & Renshaw 16th Annual Global Investment Conference in New York, NY. The presentation will take place on Wednesday, September 10th at 2:05 p.m. ET.

A live webcast will be available at this link or can be accessed by visiting "Events & Presentations" in the Investors and Media section of the Company's website at www.onconova.com. An archived replay of the webcast will be available on the Company's website for 30 days after the conference.

About Onconova Therapeutics, Inc.

Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer. Onconova's clinical and pre-clinical stage drug development candidates are derived from its extensive chemical library and are designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. In addition to rigosertib, the Company's most advanced product candidate, two other candidates are in clinical trials, and several candidates are in pre-clinical stages. For more information, please visit http://www.onconova.com.

CONTACT: Onconova Therapeutics Benjamin Hoffman, 267-759-3036 bhoffman@onconova.us Media: MacDougall Biomedical Communications Chris Erdman, 781-235-3060 chris@macbiocom.com

Hey, check out all the research scientist jobs. Post your resume today!

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES